Clinical Trial Update: A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating an EGF cancer vaccination in late-stage non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGF Cancer Vaccination

Snippet

Sponsor: Bioven Europe | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED